CY2020014I1 - Σχημα δοσολογιας ενος αγωνιστη υποδοχεα s1p - Google Patents

Σχημα δοσολογιας ενος αγωνιστη υποδοχεα s1p

Info

Publication number
CY2020014I1
CY2020014I1 CY2020014C CY2020014C CY2020014I1 CY 2020014 I1 CY2020014 I1 CY 2020014I1 CY 2020014 C CY2020014 C CY 2020014C CY 2020014 C CY2020014 C CY 2020014C CY 2020014 I1 CY2020014 I1 CY 2020014I1
Authority
CY
Cyprus
Prior art keywords
dosage schedule
receptor agent
receptor
agent
schedule
Prior art date
Application number
CY2020014C
Other languages
English (en)
Other versions
CY2020014I2 (el
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41435196&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2020014(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY2020014I1 publication Critical patent/CY2020014I1/el
Publication of CY2020014I2 publication Critical patent/CY2020014I2/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
CY2020014C 2008-12-22 2020-06-19 Σχημα δοσολογιας ενος αγωνιστη υποδοχεα s1p CY2020014I2 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13967308P 2008-12-22 2008-12-22
EP09167209 2009-08-04
PCT/EP2009/067618 WO2010072703A1 (en) 2008-12-22 2009-12-21 Dosage regimen of an s1p receptor agonist
EP09793546.4A EP2379069B1 (en) 2008-12-22 2009-12-21 Dosage regimen of an s1p receptor agonist

Publications (2)

Publication Number Publication Date
CY2020014I1 true CY2020014I1 (el) 2020-11-25
CY2020014I2 CY2020014I2 (el) 2020-11-25

Family

ID=41435196

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20151100469T CY1116321T1 (el) 2008-12-22 2015-05-27 Σχημα δοσολογιας ενος αγωνιστη υποδοχεα s1p
CY2020014C CY2020014I2 (el) 2008-12-22 2020-06-19 Σχημα δοσολογιας ενος αγωνιστη υποδοχεα s1p

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20151100469T CY1116321T1 (el) 2008-12-22 2015-05-27 Σχημα δοσολογιας ενος αγωνιστη υποδοχεα s1p

Country Status (35)

Country Link
US (2) US8492441B2 (el)
EP (1) EP2379069B1 (el)
JP (2) JP5657565B2 (el)
KR (1) KR101660555B1 (el)
CN (2) CN105213372A (el)
AR (1) AR074825A1 (el)
AU (1) AU2009331582B2 (el)
BR (1) BRPI0923213A2 (el)
CA (3) CA2747992C (el)
CY (2) CY1116321T1 (el)
DK (1) DK2379069T3 (el)
ES (1) ES2538413T3 (el)
FR (1) FR20C1022I2 (el)
HK (1) HK1159524A1 (el)
HR (1) HRP20150567T1 (el)
HU (2) HUE026400T2 (el)
IL (2) IL294658A (el)
JO (1) JO3044B1 (el)
LT (1) LTC2379069I2 (el)
LU (1) LUC00160I2 (el)
MA (1) MA32907B1 (el)
MX (2) MX2011006625A (el)
NL (1) NL301046I2 (el)
NO (1) NO2020017I1 (el)
NZ (1) NZ593427A (el)
PL (1) PL2379069T3 (el)
PT (1) PT2379069E (el)
RU (1) RU2561681C2 (el)
SG (1) SG171888A1 (el)
SI (1) SI2379069T1 (el)
TN (1) TN2011000281A1 (el)
TW (1) TWI472327B (el)
UY (1) UY32350A (el)
WO (1) WO2010072703A1 (el)
ZA (1) ZA201104102B (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009227629B2 (en) 2008-03-17 2014-09-04 Actelion Pharmaceuticals Ltd Dosing regimen for a selective S1P1 receptor agonist
SI2307007T1 (sl) * 2008-07-23 2014-11-28 Novartis Ag Modulatorji sfingozin 1 fosfatnega receptorja in njihova uporaba za zdravljenje mišičnega vnetja
ES2760607T3 (es) * 2008-12-22 2020-05-14 Novartis Ag Régimen de dosificación para un agonista del receptor s1p
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
BR112012028248A2 (pt) * 2010-05-06 2016-08-02 Novartis Ag derivados de sulfeto de diarila, seu uso, e kit
EP2455080A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
MX357304B (es) 2011-01-07 2018-07-04 Novartis Ag Formulaciones inmunosupresoras.
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
SG11201401065RA (en) * 2011-10-21 2014-09-26 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
JP6322630B2 (ja) 2012-08-17 2018-05-09 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ （２Ｚ，５Ｚ）−５−（３−クロロ−４−（（Ｒ）−２，３−ジヒドロキシプロポキシ）ベンジリデン）−２−（プロピルイミノ）−３−（ｏ−トリル）チアゾリジン−４−オンの製造方法及び前記方法において使用される中間体
JP6240746B2 (ja) 2013-04-04 2017-11-29 ノバルティス アーゲー Ｓ１ｐ受容体調節剤投与に対する患者の応答の同定
AU2015246038C1 (en) * 2014-04-10 2018-05-31 Novartis Ag Immunosuppressant formulation
JP6674903B2 (ja) * 2014-04-10 2020-04-01 ノバルティス アーゲー Ｓ１ｐ調節剤即時放出投与レジメン
WO2016091996A1 (en) 2014-12-11 2016-06-16 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist
UA126268C2 (uk) * 2015-01-06 2022-09-14 Арена Фармасьютікалз, Інк. СПОСОБИ ЛІКУВАННЯ СТАНІВ, ПОВ'ЯЗАНИХ З РЕЦЕПТОРОМ S1P<sub>1 </sub>
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
EA201890096A1 (ru) 2015-06-22 2018-08-31 Арена Фармасьютикалз, Инк. КРИСТАЛЛИЧЕСКАЯ L-АРГИНИНОВАЯ СОЛЬ (R)-2-(7-(4-ЦИКЛОПЕНТИЛ-3-(ТРИФТОРМЕТИЛ)БЕНЗИЛОКСИ)-1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ (СОЕДИНЕНИЯ 1) ДЛЯ ПРИМЕНЕНИЯ ПРИ РАССТРОЙСТВАХ, СВЯЗАННЫХ С S1P-РЕЦЕПТОРОМ
KR20190113955A (ko) 2017-02-16 2019-10-08 아레나 파마슈티칼스, 인크. 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11046646B2 (en) 2017-08-09 2021-06-29 Bristol-Myers Squibb Company Alkylphenyl compounds
WO2019032631A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company OXIME ETHER COMPOUNDS
WO2019064212A1 (en) * 2017-09-29 2019-04-04 Novartis Ag DOSAGE DIAGRAM OF SIPONIMOD
CA3074416A1 (en) * 2017-09-29 2019-04-04 Novartis Ag Dosing regimen of siponimod
EP4051250A1 (en) 2019-10-31 2022-09-07 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator
WO2021158848A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor agonist
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator
TW202245742A (zh) 2021-02-08 2022-12-01 愛爾蘭商博士健康愛爾蘭有限公司 預防、治療或改善潰瘍性結腸炎的方法
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1176819A (zh) * 1997-09-03 1998-03-25 王树生 一种解酒饮料及其制备方法
DE60324416D1 (de) 2002-05-16 2008-12-11 Novartis Ag Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
US7417065B2 (en) 2003-05-19 2008-08-26 Irm Llc Immunosuppressant compounds and compositions
ES2405404T3 (es) * 2003-10-29 2013-05-31 Wyeth Llc Composiciones farmacéuticas de liberación sostenida que comprenden aplindore y sus derivados
CN1913892A (zh) 2003-12-17 2007-02-14 大日本住友制药株式会社 药物组合物及联合药物
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
KR20070085465A (ko) * 2004-11-29 2007-08-27 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
ES2389666T3 (es) * 2005-09-09 2012-10-30 Angelini Labopharm, Llc Composición de trazodona para una administración de una vez al día
WO2008072056A1 (en) * 2006-12-14 2008-06-19 Pfizer Limited Use of mtp inhibitors for the treatment of obesity using low doses and dose-escalation
DE102007019417A1 (de) * 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
KR101600098B1 (ko) * 2007-10-12 2016-03-04 노파르티스 아게 스핑고신 1 포스페이트 (ｓ1ｐ) 수용체 조절제를 포함하는 조성물

Also Published As

Publication number Publication date
MA32907B1 (fr) 2011-12-01
EP2379069B1 (en) 2015-03-04
JP5941110B2 (ja) 2016-06-29
JP5657565B2 (ja) 2015-01-21
US20110039818A1 (en) 2011-02-17
IL213347A0 (en) 2011-07-31
CA2981830A1 (en) 2010-07-01
DK2379069T3 (en) 2015-06-08
LTC2379069I2 (lt) 2022-05-25
AU2009331582B2 (en) 2014-03-13
BRPI0923213A2 (pt) 2016-01-26
US20130281712A1 (en) 2013-10-24
TWI472327B (zh) 2015-02-11
JO3044B1 (ar) 2016-09-05
LTPA2020513I1 (lt) 2020-07-27
CA2747992A1 (en) 2010-07-01
KR20110106399A (ko) 2011-09-28
PL2379069T3 (pl) 2015-08-31
FR20C1022I2 (fr) 2021-06-11
AR074825A1 (es) 2011-02-16
JP2015038097A (ja) 2015-02-26
HK1159524A1 (en) 2012-08-03
FR20C1022I1 (el) 2020-07-31
KR101660555B1 (ko) 2016-09-27
US8492441B2 (en) 2013-07-23
IL213347B (en) 2019-11-28
NZ593427A (en) 2013-11-29
TW201028147A (en) 2010-08-01
AU2009331582A1 (en) 2011-06-30
CN102264363A (zh) 2011-11-30
CA2747992C (en) 2017-11-07
MX367667B (es) 2019-08-30
CN105213372A (zh) 2016-01-06
HUE026400T2 (en) 2016-06-28
HUS2000017I1 (hu) 2020-07-28
SI2379069T1 (sl) 2015-07-31
CY2020014I2 (el) 2020-11-25
MX2011006625A (es) 2011-09-28
UY32350A (es) 2010-04-30
TN2011000281A1 (en) 2012-12-17
NL301046I1 (nl) 2020-06-17
ES2538413T3 (es) 2015-06-19
CY1116321T1 (el) 2017-02-08
HRP20150567T1 (hr) 2015-08-14
RU2561681C2 (ru) 2015-08-27
SG171888A1 (en) 2011-07-28
EP2379069A1 (en) 2011-10-26
CA3105857A1 (en) 2010-07-01
CA3105857C (en) 2023-08-01
WO2010072703A1 (en) 2010-07-01
NO2020017I1 (no) 2020-06-17
LUC00160I2 (el) 2021-07-06
JP2012513378A (ja) 2012-06-14
IL294658A (en) 2022-09-01
NL301046I2 (nl) 2020-07-29
LUC00160I1 (el) 2020-06-19
ZA201104102B (en) 2012-02-29
PT2379069E (pt) 2015-07-03

Similar Documents

Publication Publication Date Title
CY2020014I2 (el) Σχημα δοσολογιας ενος αγωνιστη υποδοχεα s1p
CY2020036I1 (el) Δοσολογικο σχημα για εναν αγωνιστη του υποδοχεα s1p
CY2019031I1 (el) Αναπνευστικη απελευθερωση ενεργων παραγοντων
LTPA2020529I1 (lt) Sfingozino fosfato receptorių nauji moduliatoriai
SMT201600222B (it) Formulazione di anticorpi
HRP20171421T1 (hr) Kruti oblici doziranja bendamustina
ES1070518Y (es) Dispositivo nivelador para la colocacion de piezas de recubrimiento
DK3192520T3 (da) Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
BRPI1011587A2 (pt) compostos e composições terapèuticas
BRPI0916931A2 (pt) agentes terapêuticos
BR112012006957A2 (pt) regime de dosagem de um modulador de receptor de s1p
DK2367542T3 (da) Orale doseringsformer af bendamustin
SMT201500123B (it) Dosaggio unitario di apadenoson
BRPI0909764A2 (pt) compostos terapêuticos
BRPI0906879A2 (pt) Compostos terapêuticos
TH116164B (th) การรวมกันของสารประกอบออกฤทธิ์
TH120083B (th) การรวมกันของสารประกอบออกฤทธิ์
ES1065747Y (es) Pieza de union central para mosquiteras
UA17730S (uk) Набір пристроїв для з`єднання щитів опалубки
DK2257548T3 (da) Terapeutiske forbindelser
TH115366B (th) รูปแบบขนาดยาของแข็ง